Literature DB >> 31215668

Case of dermatomyositis during treatment with pembrolizumab for lung cancer.

Haruna Hinogami1, Chigusa Yamashita1, Aya Tanaka1, Hirohiko Shirai1, Yoshio Nakano2, Yoshinobu Matsuura3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31215668     DOI: 10.1111/1346-8138.14993

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  2 in total

1.  Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung.

Authors:  Claire J Wiggins; Susan Y Chon
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-27

2.  Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis.

Authors:  Naoki Hamada; Ayaka Maeda; Kaoru Takase-Minegishi; Yohei Kirino; Yumiko Sugiyama; Ho Namkoong; Nobuyuki Horita; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2021-12-06       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.